3360-79-0

Usage

Uses

Used in Chemical Synthesis:
4-Methoxy-N-methyl-2-nitrobenzenamine is used as a chemical precursor for the synthesis of more complex structures. Its functional groups allow for further reactions and modifications, making it a valuable intermediate in the production of various organic compounds.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 4-Methoxy-N-methyl-2-nitrobenzenamine is used as a building block for the development of new drugs. Its structural features can be exploited to create molecules with specific therapeutic properties, potentially leading to the discovery of novel medications.
Used in Research and Development:
4-Methoxy-N-methyl-2-nitrobenzenamine is utilized in research settings to study the properties and reactions of nitroanilines. Its behavior in various chemical processes can provide insights into the development of new synthetic methods and the understanding of reaction mechanisms.
Used in Material Science:
In material science, 4-Methoxy-N-methyl-2-nitrobenzenamine may be used as a component in the development of new materials with specific properties. Its incorporation into polymers or other materials could lead to advancements in areas such as electronics, coatings, or adhesives.

InChI:InChI=1/C8H10N2O3/c1-9-7-4-3-6(13-2)5-8(7)10(11)12/h3-5,9H,1-2H3

Upstream product

• 3360-80-3 toluene-4-sulfonic acid-(4-methoxy-N-methyl-2-nitro-anilide) 
• 67-56-1 methanol 
• 85020-96-8 acetic acid-(4-methoxy-N-methyl-2-nitro-anilide) 
• 85122-54-9 3-nitro-4(benzotriazol-1-ylmethyl)aminoanisole 
• 128691-93-0 4-methoxy-2-nitrotrifluoroacetanilide 
• 77-78-1 dimethyl sulfate 
• 22809-78-5 N-(4-methoxyphenyl)-N-methylnitramine 
• 74-88-4 methyl iodide 
• 96-96-8 4-methoxy-2-nitroaniline 
• 119-81-3 4-methoxy-2-nitroacetanilide 
• 51-66-1 4-methoxyacetanilide 
• 1150-26-1 N-(4-Methoxy-phenyl)-4-methyl-benzenesulfonamide 
• 3360-81-4 N-(4-methoxy-2-nitrophenyl)-4-methylbenzenesulfonamide 
• 74-89-5 methylamine 

Downstream Products

• 85020-96-8 acetic acid-(4-methoxy-N-methyl-2-nitro-anilide) 
• 61154-57-2 [(4-Methoxy-2-nitro-phenyl)-methyl-sulfamoyl]-acetic acid ethyl ester 
• 344767-35-7 Naphthalene-1,7-dicarboxylic acid bis-[(4-methoxy-2-nitro-phenyl)-methyl-amide] 
• 213118-54-8 1-(2-Amino-4-chloro-phenyl)-1,3-dimethyl-urea 
• 213118-53-7 1-(2-Amino-4-methoxy-phenyl)-1,3-dimethyl-urea 
• 3360-78-9 4-methoxy-N-methyl-1,2-phenylenediamine 
• 80776-49-4 1-Methyl-6-methoxy-1,4-dihydroquinoxalin-2,3-dione 
• 36242-33-8 N-methyl N-carboethoxy acetyl 2-nitro 4-methoxy aniline 
• 1450610-28-2 C₁₂H₁₆N₂O₅ 
• 1450610-30-6 C₁₁H₁₆N₄O₄ 
• 1190761-82-0 3-(2-((4-methoxy-2-nitrophenyl)(methyl)amino)ethyl)-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide 
• 1450610-34-0 C₁₁H₁₃N₃O₄ 
• 50591-22-5 1-methyl-1H-benzo[d]imidazol-5-ol 
• 68426-83-5 (5-methoxy-1-methyl-1H-benzo[d]imidazol-2-yl)methanol 

Relevant academic research and scientific papers

Cu-Catalyzed C-H Allylation of Benzimidazoles with Allenes

CuH-catalyzed intramolecular cyclization and intermolecular allylation of benzimidazoles with allenes have been described. The reaction proceeded smoothly with the catalytic system of Cu(OAc)2/Xantphos and catalytic amount of (MeO)2MeSiH. This protocol features mild reaction conditions and a good tolerance of substrates bearing electron-withdrawing, electron-donating, or electron-neutral groups. A new catalytic mechanism was proposed for this copper hydride catalytic system.

Lysophosphatidic acid receptor antagonists and preparation method thereof

The invention belongs to the technical field of medicinal chemistry, and particularly relates to lysophosphatidic acid receptor antagonists and a preparation method thereof. The applicant surprisinglyfinds that compounds provided by the invention have high LPAR1 antagonistic activity and selectivity, low toxicity, good metabolic stability and good drug development prospect, and can be used for preventing or treating diseases or symptoms related to LPAR1. The applicant also accidentally finds that the IC50 value of part of the compounds can be as low as 300 nM or below and even 50 nM or below.Moreover, the compounds disclosed by the invention have better safety, and the CC50 range of the compounds can reach 200 [mu]M or above. In addition, the compounds of the present invention have goodmetabolic stability in humans, rats, and mice, such excellent inhibitory activity being very desirable for their use as LPAR1 inhibitors in the above diseases or disorders. In addition, the preparation method of the compounds is simple, mild in reaction condition, high in product yield and suitable for industrial production.

INHIBITORS OF VAP-1

Provided herein are compounds and methods of use thereof for the modulation of VAP-1 activity.

ERBB RECEPTOR INHIBITORS

Disclosed are compounds inhibiting ErbBs (e. g. HER2), pharmaceutically acceptable salts, hydrates, solvates or stereoisomers thereof and pharmaceutical compositions comprising the compounds. The compound and the pharmaceutical composition can effectively treat diseases associated ErbBs (especially HER2), including cancer.

Development of a Selective Inhibitor of Protein Arginine Deiminase 2

Protein arginine deiminase 2 (PAD2) plays a key role in the onset and progression of multiple sclerosis, rheumatoid arthritis, and breast cancer. To date, no PAD2-selective inhibitor has been developed. Such a compound will be critical for elucidating the

IRE-1α INHIBITORS

PROBLEM TO BE SOLVED: To provide compounds which directly inhibit inositol requiring enzyme 1 (IRE-1α activity) in vitro, prodrugs, and pharmaceutically acceptable salts thereof. SOLUTION: The present invention provides a compound represented by formula (A) [R3 and R4 are H or the like; Q5-Q8, together with the benzene ring to which they are attached, form a benzofused ring, where at least one of Q5-Q8 is a heteroatom selected from N, O, and S. COPYRIGHT: (C)2016,JPOandINPIT

Amino Azaxylylenes Photogenerated from o-Amido Imines: Photoassisted Access to Complex Spiro-Poly-Heterocycles

Upon irradiation, cyclic imines containing o-amido groups are shown to produce reactive intermediates, amino azaxylylenes, which undergo intramolecular cycloadditions to tethered unsaturated pendants to yield complex N,O-heterocycles having an additional spiro-connected nitrogen heterocyclic moiety. Modular assembly of the photoprecursors allows expeditious increase of the complexity of the target poly-heterocyclic scaffolds with a minimal number of experimentally simple reaction steps. The photocyclization and subsequent postphotochemical transformations are accompanied by an increase of Lovering's fsp3 factor, thus producing unprecedented three-dimensional molecular architectures, and offering extended sampling of chemical space. Rings in three dimensions: Cyclic imines containing an o-amido group undergo excited-state intramolecular proton transfer to generate amino azaxylylenes. The amino azaxylylenes undergo intramolecular cycloadditions to tethered unsaturated pendants to yield complex heterocyclic three-dimensional molecular architectures.

ALDOSTERONE SYNTHASE INHIBITORS

The invention involves compounds of structural Formula (I) and the pharmaceutically acceptable salts thereof. The compounds of the invention are effective at selectively inhibiting CYP11B2, and are therefore useful for the treatment or prophylaxis of disorders that are associated with elevated aldosterone levels, including, but not limited to, hypertension and heart failure.

Benzimidazole- and benzothiazole-quinones: Excellent substrates for NAD(P)H:quinone oxidoreductase 1

A series of benzimidazole- and benzothiazole-quinones has been synthesized. The ability of these heterocyclic quinones to act as substrates for recombinant human NAD(P)H:quinone oxidoreductase (NQO1), a two-electron reductase upregulated in tumour cells,

Therapeutic diphenyl ether ligands

This invention is directed to compounds of formula Ia, Ib or Ic and to pharmaceutical compositions thereof: or a prodrug thereof and a pharmaceutically acceptable carrier, wherein the R groups are defined in the specification; and, in which the dashed line represents an optional double bond. The invention is also directed to methods of treating, diagnosing, and preventing disorders of the central nervous system that are associated with 5HT receptors, including obesity, attention deficit disorder, migraine, depression, epilepsy, anxiety, Alzheimer's disease, withdrawal from drug abuse, pain, schizophrenia, stress-related disorders, panic disorder, sleep disorders, phobias, obsessive compulsive disorder, post-traumatic-stress syndrome, immune system depression, stress-induced gastrointestinal dysfunction, stress-induced cardiovascular dysfunction, and sexual dysfunction.